Breaking News

Financial Report: Lilly

January 28, 2016

Novartis Animal Health revenues drive growth in the quarter

Lilly
 
4Q Revenues: $5.4 billion (+5%)

4Q Earnings: $478.4 million (+12%)

FY Revenues: $20.0 billion (+2%)

FY Earnings: $2.4 billion (+1%)

Comments: Revenue in the U.S. increased 15% to $2.8 billion in the quarter. Growth in the quarter was primarily due to the inclusion of Novartis Animal Health revenue ($811.7 million, up 28%) and diabetes drugs Trulicity ($112.5 million), and Cyramza ($117.5 million), as well as Erbitux ($176.2 million, up 83%) due to the transfer of commercialization rights in North America. These increases were partially offset by the residual impact of the loss of exclusivity for Cymbalta ($223.6 million, down 39%). Humalog sales were up 10% to $798.7 million. Alimta sales were $627.2 million down 13%. Cialis sales were $638.4 million, up 3%. Forteo sales were $377.9 million, down 1%. Humulin sales were $358.6 million, down 9%. Strattera sales were up 14% to $221.6 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks